-
公开(公告)号：EP3016954B1
公开(公告)日：2018-10-31
申请号：EP14735966.5
申请日：2014-07-04
申请人： Sandoz AG
IPC分类号： C07D487/04 , A61K31/55 , A61P35/00
CPC分类号： C07D487/04 , A61K9/2009 , A61K9/2018 , A61K9/2054 , A61K9/2059
摘要： The present disclosure relates to polymorphic forms of the hydrochloride salt of ponatinib (“compound 1”) and to processes for the preparation of these polymorphic forms. The present disclosure also generally relates to a pharmaceutical composition comprising the forms, as well of methods of using the form(s) in the treatment of disorders associated with pathological cellular proliferation, such as neoplasms, and cancer.
-
2.发明公开CRYSTALLINE FORMS OF CABOZANTINIB PHOSPHATE AND CABOZANTINIB HYDROCHLORIDE 有权CABOZANTINIB PHOSPHATE和CABOZANTINIB HYDROCHLORIDE的结晶形式
公开(公告)号：EP3274332A1
公开(公告)日：2018-01-31
申请号：EP16710997.4
申请日：2016-03-22
申请人： Sandoz AG
IPC分类号： C07D215/22 , A61K31/47 , A61P35/00
CPC分类号： C07D215/233 , A61P35/00 , C07B2200/13 , C07D215/22
摘要： The present invention relates to crystalline forms of cabozantinib phosphoric acid salt and cabozantinib hydrochloric acid salt and to a method for their preparation. Furthermore, the invention relates to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments. Cabozantinib, i.e. N-{4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl}-N′-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide is represented by the chemical structure: Formula.
-
公开(公告)号：EP3274333B1
公开(公告)日：2019-04-24
申请号：EP16711818.1
申请日：2016-03-22
申请人： Sandoz AG
IPC分类号： C07D215/22 , A61K31/47 , A61P35/00
-
公开(公告)号：EP3274333A1
公开(公告)日：2018-01-31
申请号：EP16711818.1
申请日：2016-03-22
申请人： Sandoz AG
IPC分类号： C07D215/22 , A61K31/47 , A61P35/00
CPC分类号： A61K31/47 , A61P35/00 , C07D215/20 , C07D215/22
摘要： The present invention relates to crystalline forms of cabozantinib succinate (Form A) and cabozantinib acetate (Form A-1) and to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments.
-
公开(公告)号：EP4041396A1
公开(公告)日：2022-08-17
申请号：EP20789571.5
申请日：2020-10-08
申请人： Sandoz AG
IPC分类号： A61P35/00 , C07D498/18 , A61K31/439
-
公开(公告)号：EP3866923A1
公开(公告)日：2021-08-25
申请号：EP19786980.3
申请日：2019-10-16
申请人： Sandoz AG
IPC分类号： A61P5/00 , C07C25/00 , A61K31/198
-
公开(公告)号：EP3704124A1
公开(公告)日：2020-09-09
申请号：EP18795631.3
申请日：2018-10-31
申请人： Sandoz AG
发明人： STEFINOVIC, Marijan
IPC分类号： C07D487/06 , C07C309/04 , A61P35/00
-
公开(公告)号：EP2950803A1
公开(公告)日：2015-12-09
申请号：EP14701563.0
申请日：2014-01-28
申请人： Sandoz AG
摘要： Linaclotide is a guanylate cyclase type C receptor (GCC) agonist used in the treatment of gastrointestinal disorders and conditions, including irritable bowel syndrome and chronic constipation. Crystalline form II of Linaclotide is prepared in high purity and yields and shows superior chemical stability in comparison to known crystal or amorphous forms of Linaclotide. A process for the purification of Linaclotide is also provided.
-
公开(公告)号：EP3585787A1
公开(公告)日：2020-01-01
申请号：EP18701772.8
申请日：2018-02-01
申请人： Sandoz AG
IPC分类号： C07D471/04 , A61K31/4375 , A61P25/14
-
公开(公告)号：EP3357909A1
公开(公告)日：2018-08-08
申请号：EP17154412.5
申请日：2017-02-02
申请人： Sandoz AG
IPC分类号： C07D211/24 , A61K31/451 , A61P25/28
CPC分类号： C07D211/24
摘要： The present invention relates to crystalline pridopidine free base and a process for its preparation. The invention also relates to a pharmaceutical composition comprising crystalline pridopidine free base and one or more pharmaceutically acceptable ingredients and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of Huntington's disease.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.011 秒)
